Generic antifungal drug put to the test in healthy volunteers
NCT ID NCT06977490
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checked if a new version of the antifungal drug amphotericin B liposome works the same as the original. 42 healthy adults received a single dose of each version at different times. The goal was to see if the drug levels in the blood were similar enough to consider the two versions interchangeable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinan Central Hospital, No.105, Jiefang Road,
Jinan, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Blood test clues could make antifungal dosing safer for transplant patients
- Leukemia Patients' hidden threat: fungal infections under microscope
- Tiny study aims to Fine-Tune fungal drug dosing during plasma exchange
- Scientists probe hidden causes of deadly parasite relapse in HIV patients